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Abstract
Lactoferrin (LF), a key element in mammalian immune system, plays pivotal roles in host defence against infection and
excessive inflammation. Its protective effects range from direct antimicrobial activities against a large panel of microbes,
including bacteria, viruses, fungi and parasites, to antinflammatory and anticancer activities. In this study, we show that
monocyte-derived dendritic cells (MD-DCs) generated in the presence of bovine LF (bLF) fail to undergo activation by up-
modulating CD83, co-stimulatory and major histocompatibility complex molecules, and cytokine/chemokine secretion.
Moreover, these cells are weak activators of T cell proliferation and retain antigen uptake activity. Consistent with an
impaired maturation, bLF-MD-DC primed T lymphocytes exhibit a functional unresponsiveness characterized by reduced
expression of CD154 and impaired expression of IFN-c and IL-2. The observed imunosuppressive effects correlate with an
increased expression of molecules with negative regulatory functions (i.e. immunoglobulin-like transcript 3 and
programmed death ligand 1), indoleamine 2,3-dioxygenase, and suppressor of cytokine signaling-3. Interestingly, bLF-
MD-DCs produce IL-6 and exhibit constitutive signal transducer and activator of transcription 3 activation. Conversely, bLF
exposure of already differentiated MD-DCs completely fails to induce IL-6, and partially inhibits Toll-like receptor (TLR)
agonist-induced activation. Cell-specific differences in bLF internalization likely account for the distinct response elicited by
bLF in monocytes versus immature DCs, providing a mechanistic base for its multiple effects. These results indicate that bLF
exerts a potent anti-inflammatory activity by skewing monocyte differentiation into DCs with impaired capacity to undergo
activation and to promote Th1 responses. Overall, these bLF-mediated effects may represent a strategy to block excessive
DC activation upon TLR-induced inflammation, adding further evidence for a critical role of bLF in directing host immune
function.
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Introduction
Lactoferrin (LF) is an 80 kDa iron-binding glycoprotein
abundantly found in most biological fluids of mammals, which
binds with high affinity two ferric ions per molecule [1]. It is
secreted in an iron-free form from many mucosal epithelia cells,
and released by neutrophils during inflammation. LF is now
recognized as a key element in the host defence system [2,3,4]. In
addition to the antimicrobial properties, both human recombinant
and bovine native LFs exhibit a variety of effects on the host
immune system, ranging from inhibition of inflammation to
promotion of both innate and adaptive immune responses [2,5].
Although the mechanisms underlying LF immunomodulatory
properties have not been fully elucidated yet, evidence indicates
that the capacity of this molecule to directly interact with antigen
presenting cells (APCs), i.e. monocytes/macrophages and dendrit-
ic cells (DCs) may play a critical role. At the cellular level, LF
modulates important aspects of APC biology, including migration
and cell activation, whereas at the molecular level it affects
expression of soluble immune mediators, such as cytokines,
chemokines and other effector molecules, thus contributing to
the regulation of inflammation and immunity [2,5].
Among APCs, monocytes/macrophages and DCs are of critical
importance for the maintenance of tissue homeostasis and innate
response to pathogens, as well as in linking innate to adaptive
immune response. Monocytes/macrophages are highly phagocytic
cells which play a central role in the control of infection, either by
direct intracellular killing of microorganisms or by secreting
cytokines inhibiting their replication, as well as in type II
inflammation and tissue repair processes [6,7]. DCs are a
heterogeneous population of cells highly specialized for antigen
recognition that play a key role in the immune system by virtue of
their capacity to control both immune activation and tolerance
induction [8,9]. Inflammatory mediators and especially the Toll
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pivotal role in inducing the immune activation program in DCs.
The activation of resting DCs is a crucial step in the initiation of
adaptive immunity as it links peripheral events initiated by the
encounter with pathogens to the activation and expansion of
antigen specific T lymphocytes in secondary lymphoid organs
[10].
However, accumulated evidence highlights the functional
plasticity of DCs, which are also able to drive antigen-specific
unresponsiveness or tolerance in central lymphoid organs and in
the periphery, and to contribute to the expansion and differen-
tiation of T cells that regulate or suppress other immune T cells
[11].
In the present study, we report that bovine LF (bLF) acts as a
potent anti-inflammatory agent on monocytes by triggering a
tolerogenic-like program during their differentiation into DCs.
MD-DCs generated in the presence of bLF show enhanced
expression or activation of molecules characterizing tolerogenic
DCs, and constitutively secrete IL-6. Consistent with their
phenotypic features, T lymphocytes expanded in bLF-exposed
DC/T lymphocyte co-cultures are anergic and produce little IFN-
c and IL-2. Major differences have been observed in the capacity
of monocytes to internalize bLF with respect to MD-DCs thus
providing a mechanistic base for the rather divergent effects of
bLF, anti-inflammatory versus immunostimulatory, observed in
monocytes and DCs, respectively.
Overall, the capacity of LF to differently interact with specific
cell types of the immune system leading to both induction and
suppression of the immune response adds further evidence to the
pivotal role of this natural compound in the orchestration of the
immune response.
Results
Phenotypic properties of MD-DCs generated in the
presence of bLF
The expression of a panel of surface antigens, typical of
immature DCs, was analyzed in monocytes stimulated to
differentiate into classic MD-DCs in the absence or in the
continuous presence of bLF. As shown in Figure 1A, bLF did not
interfere with monocyte differentiation into MD-DCs since bLF
exposed cells at day 6 of culture expressed CD1a, CD80, CD86
and CD40, as well as MHC class I and II antigens, and barely
detectable levels of CD83 and CD14 consistent with their
differentiation into immature MD-DCs (iMD-DCs). However, a
modest but reproducible increase in the expression of CD80,
CD86 and HLA-DR, and to a higher extent of programmed death
ligand-1 (PD-L1) and immunoglobulin-like transcript 3 (ILT3) was
observed in bLF generated MD-DCs (bLF-MD-DCs) with respect
to control iMD-DCs. Conversely, ILT4 was expressed at
comparable levels in control and bLF-MD-DCs. Furthermore,
bLF influenced the dichotomy CD1a
2/CD1a
+ observed in in vitro
generated MD-DCs [12,13]. The percentage of CD1a
+ cells
monitored in ten independent monocyte cultures substantially
varied (p,0.05) when cells were differentiated in the presence of
bLF, with a preferential generation of CD1a
2 cells (mean 1866%,
n=10) with respect to control cultures (mean 863%, n=10).
Interestingly, the majority of CD1a
2 MD-DCs also expressed high
levels of HLA-DR and CD86, and some of them were positive for
the activation marker CD83 (Figure 1B). In keeping with their
immature phenotype, bLF-MD-DCs expressed high levels of
dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN)
and mannose receptor (MR), and exhibited a high capacity to
uptake dextran (DXT) (Figure 1C). Likewise, bLF-MD-DCs did
not secrete effector cytokines typical of activated DCs, including
IL-12, TNF, IL-23, IL-10 and CCL2 (see Figure 2C). Interest-
ingly, bLF-MD-DCs produced high levels of IL-6 that were not
found in control cultures (Figure 1D).
bLF generated MD-DCs do not undergo phenotypic and
functional maturation following TLR stimulation
Next we evaluated whether bLF-MD-DCs could mature in
response to TLR triggering.AsshowninFigure2A, up-modulation
of CD80, HLA-DR and CD83, consistently observed in LPS
stimulated control cultures, was markedly reduced inbLF-MD-DCs.
Structurally, LFs of different origins contain a highly basic
region close to the N-terminus which binds to a variety of anionic
biological molecules, including lipid A, with high affinity [14,15].
To exclude that the observed bLF-mediated inhibitory effect on
DC activation was due to the capacity of this molecule to sequester
LPS thus neutralizing its biological activity, we tested the effect of
bLF on the maturation induced by other TLR agonists such as the
TLR3 ligand poly(I-C). As shown in Figure 2B, poly(I-C) induced
phenotypic changes were strongly reduced in bLF-MD-DCs as
compared to control cultures. Likewise, CD83 up-modulation was
also inhibited in bLF-MD-DCs stimulated with the imidazoquino-
line compound resiquimod (R848) with respect to control cultures
(Figure S1, panel A). These results provide evidence that
inhibition of MD-DC maturation is not merely related to bLF
capacity to bind LPS but likely relies on direct effects of this
molecule on its target cells. In keeping with the lack of phenotypic
changes indicative of DC maturation, bLF-MD-DCs retained a
high capacity to uptake DXT upon activation with both LPS and
poly(I-C), consistent with an immature phenotype (Figure 2C). As
expected, the high endocytic capacity exhibited by control MD-
DCs at the immature state was markedly down-modulated upon
maturation induction with LPS or poly(I-C). Likewise, bLF-MD-
DCs treated with LPS and poly(I-C) failed to produce or produced
remarkably less IL-12 (n=6, p,0.05 for both stimuli), TNF
(n=11, p,0.001 and p,0.002 for LPS and poly(I-C), respectively),
IL-23 (n=14, p,0.05 for both stimuli) and CCL2 (n=7,p,0.05
for both stimuli) than control MD-DCs stimulated under the same
conditions (Figure 2D). Likewise, IL-12 and TNF up-modulation
was markedly inhibited in bLF-MD-DCs stimulated with R848
with respect to control cultures (Figure S1, panels B and C). In
contrast, no significant differences were observed in the production
of IL-10 that was up-modulated at a comparable extent in both
control MD-DC and bLF-MD-DC cultures stimulated with LPS
or poly(I-C) (n=7, p=0.298 and p=0.228, respectively)
(Figure 2D). These results exclude that the bLF-mediated
inhibitory effect on cytokines/chemokines relies on hyper-
production of IL-10, a cytokine well-known as a negative regulator
of IL-12 and other cytokines [16].
bLF differently interacts with DC precursor cells and
differentiated immature DCs
Previous studies demonstrated that exposure of iMD-DCs to
human recombinant LF (Talactoferrin) results in their functional
activation and promotes Th1 responses [17,18]. From the results
achieved to this point it was obvious that stimulation with bLF
during DC generation suppresses the development of functional
DCs suggesting that this molecule could differently interact with
differentiated DCs and their monocyte precursors. In fact, in our
study, cells have been treated with bLF at different time of culture,
immediately after monocytes isolation and every three days until
sample processing, thus allowing bLF to exert differential effects
on the two different cell targets.
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treatment with bLF of freshly isolated monocytes (day 0) or iMD-
DCs (day 5) on the 24 h production of IL-6. As shown in
Figure 3A, high levels of IL-6 were found in monocyte cultures
treated with bLF (n=13, p,0.01) while this cytokine was not
secreted when bLF was added to iMD-DCs (n=6, p=0.363).
Figure 1. Phenotypic characterization of iMD-DCs generated in the presence of bLF. Monocytes were stimulated to differentiate into MD-
DCs in the absence or in the continuous presence of 100 mg/ml of bLF. Bovine LF was added to the culture at day 0, 2 and 5 concomitantly to the
addition of GM-CSF and IL-4. At day 6, cells and culture supernatants were collected. (A) Cells were stained with the indicated mAbs as described in
‘‘Materials and Methods’’, and analyzed by flow cytometry. The shaded and black areas represent the expression of phenotypic markers in control and
bLF-treated cells, respectively. Numbers indicate MFI of markers analyzed on cells. One representative experiment out of 4 performed is shown. (B)
FACS dot plots show PE-conjugated CD1a versus FITC-conjugated CD86, CD83 or HLA-DR staining. Numbers indicate percentages of cells included in
each quadrant. One representative experiment out of 4 performed is shown. (C) Cells were stained with specific mAbs to DC-SIGN, MR or FITC-
conjugated DXT, and analyzed by flow cytometry. Open histograms represent the background staining of isotype-matched mAbs for DC-SIGN and
MR, or cells incubated with DXT at 0uC. Numbers indicate MFI of DC-SIGN, MR and DXT staining. One representative experiment out of 4 is shown. (D)
Six-day supernatants from bLF-treated or untreated cultures were analyzed by ELISA for IL-6 content. p values (n=8, *p,0.05) were calculated for IL-6
production in cultures exposed to bLF versus control cells.
doi:10.1371/journal.pone.0022504.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22504Figure 2. bLF-induced impairment of MD-DC maturation. Monocytes were stimulated to differentiate into iMD-DCs in the presence or in the
absence of bLF as described in the legend to Figure 1. At day 5 of culture, cells were stimulated with LPS (10 ng/ml) (A) or poly(I-C) (20 mg/ml) (B).
Twenty-four hours later, cells were collected and stained with mAbs to CD80, CD83 and HLA-DR. Open area represents staining with isotype Ab and
shaded area phenotypic markers expression in activated control and bLF-MD-DCs. One representative experiment out of 4 is shown. (C) Control and
bLF-MD-DCs were stained with DXT 24 h after LPS or poly(I-C) stimulation, and analyzed by flow cytometry. Open and black histograms represent
staining with DXT at 0uCo r3 7 uC, respectively. Numbers indicate the percentage of positive cells and MFI values. One representative experiment out
of 4 is shown. (D) Cytokine and chemokine contents in supernatants of MD-DCs stimulated with LPS or poly(I-C) for 24 h. Mean 6 SE of 6 to 14
independent experiments is shown. * p,0.05, ** p,0.01, *** p,0.001, MD-DCs versus bLF-MD-DCs.
doi:10.1371/journal.pone.0022504.g002
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expressed following bLF treatment in both freshly isolated
monocytes and iMD-DCs (data not shown). IL-6 production
entirely occurred within the first 18 h after cell seeding. In fact,
when the culture medium of bLf stimulated monocytes was
replaced with fresh medium 18 h post stimulation and cells were
cultured for additional 5 days, no IL-6 was detected in the
supernatant at the end of cultures (Figure 3B).
bLF is internalized by monocytes but not immature DCs
and accumulates into the nucleus
To explore the possibility that a different interaction of bLF
with monocytes and iMD-DCs underlies the distinct effects
mediated by this molecule, bLF uptake and internalization was
investigated by confocal microscopy in freshly isolated monocytes
and iMD-DCs. Time-course experiments revealed that bLF
was rapidly internalized in freshly isolated monocytes, and its
sub-cellular distribution was dependent on the time point
examined. As shown in Figure 4, bLF was distributed in spotted
dots in the cytoplasm of monocytes already after 10 minutes of
treatment (panels A, C, D), accumulated in the perinuclear area
after 1 h (panels E, G, H), and entered the nucleus at 3 h of
treatment, as demonstrated by merged green and blue fluores-
cence (panels K and L). Conversely, iMD-DCs failed to
internalize bLF and very few cells exhibiting some bLF
cytoplasmic staining were detected at the later time point (panels
V, X, Y). To precisely define the differentiation stage in which
changes in the capability of individual cells to respond to bLF
occur, progression of monocyte to MD-DC differentiation was
monitored in parallel with bLF internalization and IL-6 secretion.
To assess and quantify progression, percentage of CD14
+ and
CD1a
+ cells, and CD1a/CD14 median fluorescence intensity
(MFI) ratio were used as qualitative and quantitative measure of
MD-DC differentiation, respectively. As shown in Figure 5A,
monocyte to MD-DC differentiation progresses through inter-
mediate stages reflected by specific up-modulation of CD1a and
down-regulation of CD14. Day 0 monocytes were essentially all
CD1a
2 and CD14
+. At day 1, and more markedly at day 2, cells
began to express CD1a while decreasing CD14 expression. By
day 3, most cells have down-regulated CD14 and acquired the
expression of CD1a. By day 4, the majority of cells were fully
differentiated CD1a
+/CD14
2 MD-DCs. Likewise, CD1a/CD14
MFI ratio steadily increased during differentiation and showed
clustering of the numerical values at each stages of differentiation
(Figure 5B), thus providing a reliable indicator of differentiation
progression. According to these metrics, a full MD-DC
phenotype is acquired between day 3 and 4 of culture in the
presence of GM-CSF and IL-4. Concomitant analysis of bLF
uptake and internalization revealed that, at day 0 and 1 of
culture, most cells internalize bLF which localizes into the
nucleus (Figure 5C). Reduction in the percentage of cells
internalizing bLF was already observed at day 2, increased at day
3 with only half of the cells positively stained for bLF, which
mostly localized into the cytoplasm. The capacity to internalize
bLF further decreased with differentiation progression and, at
day 4 and 5 of culture, most cells did not exhibit any intracellular
bLF. In keeping with these results, reduction in IL-6 secretion
was already observed at day 2 of culture, while this cytokine was
no longer produced in response to bLF in more differentiated
cells at day 4 and 5 of culture (Figure 5D). These results suggest
an intimate relationship between differentiation progression and
capacity to internalize bLF within the nucleus. Furthermore, bLF
nuclear internalization appears to be an important requisite for
bLF-induced IL-6 expression.
Role of CD14 and its co-receptors, TLR2 and TLR4, in bLF
induced IL-6 production
LFs bind a variety of cell determinants with different grade of
specificity, including molecules involved in pathogen recognition
[1,19,20,21]. Experiments were then designed to define the role of
CD14, TLR2 and TLR4, in bLF entry and IL-6 induction.
Although blocking each of these receptors failed to affect bLF
internalization in monocytes (data not shown), blocking CD14
(n=7, p,0.01) and TLR2 (n=8, p,0.001) with specific
antibodies (Abs) strongly reduced the capacity of bLF to induce
IL-6 (Figure 6). However, only a partial but significant reduction
of IL-6 secretion was achieved when Abs against TLR4 (n=7,
p,0.05) were added to the cultures. Conversely, isotype control
Abs did not show any effect. These results further support the
hypothesis that, through CD14, bLF could preferentially target
monocytes in the initial phases of DC differentiation.
Figure 3. bLF induces an early and transient IL-6 production in
DC precursor cells but not in iMD-DCs. Monocytes were treated
with bLF, in the presence of GM-CSF and IL-4. (A) bLF was added once
to cultures soon after seeding (day 0) or at day 5. Controls were left
untreated (none). At day 6, supernatants were assessed for IL-6 content.
The results of independent experiments are shown (bLF day 0 versus
untreated, n=13, **p,0.01). (B) Cells were treated with bLF for 18 h,
then the culture medium was replaced with fresh medium containing
GM-CSF and IL-4, and cells cultured for additional 5 days. IL-6 secreted
in the 18 h and 5 day conditioned medium was titrated by ELISA. Mean
6 SE of 5 independent experiments is shown (*** p,0.001).
doi:10.1371/journal.pone.0022504.g003
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activation
Previous studies demonstrated that IL-6 plays a major role in
maintaining DCs at an immature state both in vivo and in vitro [22].
Importantly, signal transducer and activator of transcription 3
(STAT3) activation by IL-6 is required for the IL-6 mediated
suppression of DC maturation in vivo [23]. Furthermore, STAT3
activation has been linked to the induction of DCs with a
tolerogenic phenotype [24,25,26]. To address the issue of whether
IL-6/STAT3 signalling could play a role in the inhibitory effect of
bLF on DC activation, cell lysates prepared from control iMD-
DCs and bLF-MD-DCs were analyzed for the presence of tyrosine
phosphorylated STAT3. As shown in Figure 7A, while
phosphorylated STAT3 was not detected in control MD-DCs,
bLF-MD-DCs exhibited high levels of the phosphorylated form.
STAT3 activation strongly depended on IL-6 since blocking the
biological activity of this cytokine with specific neutralizing
Abs markedly reduced the levels of phosphorylated STAT3
Figure 4. Differential bLF internalization in monocytes and iMD-DCs. CLSM images of cell-associated bLF in monocytes and MD-DCs treated
once with bLF (100 mg/ml) soon after seeding or after 6 days of culture, respectively, at the indicated time-points after treatment. Images taken at
level of the nuclear section of one representative experiment out of 3 performed are shown. Single green and blue fluorescences represent bLF
(panels A, E, I, M, R, V) and nuclei (panels B, F, J, N, S, W), respectively. Panels C, G, K, O, T, X, and their respective 26magnification (panels D, H, L, P, U.
Y) show merged green and blue fluorescence.
doi:10.1371/journal.pone.0022504.g004
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22504Figure 5. bLF internalization during monocyte to MD-DC differentiation progression. Monocytes were stimulated to differenziate into
MD-DCs in the presence of GM-CSF and IL-4. (A) Flow cytometric analysis showing cell-surface phenotype during MD-DC differentiation. Monocytes
and DCs can be distinguished by their CD14 and CD1a expression profiles. Data from one representative donor out of 5 are shown. (B) Quantification
of CD1a/CD14 expression ratios in 5 independent donors. Ratios were calculated using MFI of CD1a/MFI of CD14 and normalized to the day 5 ratio of
each donor, which was set at 1.0. (C) Monocytes were exposed to bLF soon after seeding (day 0) or at day 1, 2, 3, 4 or 5 of culture. Three hours later,
bLF internalization was assessed by CLSM. Figure shows the mean 6 SE of bLF positive cells in 3 independent experiments. The percentage of
positive cells was calculated by analyzing at least 350 cells for each experimental point. The nuclear or cytoplasmatic positivity is also indicated.
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in bLF-MD-DC cultures treated with the isotype control Ab
(Figure 6A). Despite the fact that STAT3 activation strongly
relies on IL-6, blocking the biological activity of this cytokine did
not rescue the capacity of bLF-MD-DCs to undergo maturation as
assessed by CD83 expression, TNF and IL-12 secretion
(Figure 7B). However, replacement of culture medium 18 h
after bLF addition, thus depleting bLF-induced soluble factors and
residual bLF, partially restored the capacity of bLF-MD-DCs to
respond to LPS as assessed by restoration of LPS-induced CD83
up-modulation, and partial rescue of TNF, but not IL-12
production (Figure 7C). Conversely, bLF addition to day 5
iMD-DCs did not block LPS-induced CD83 up-modulation while
completely abrogated IL-12 and TNF secretion when the culture
medium was not replaced. As expected, replacement of culture
medium 18 h after bLF addition did not interfere with MD-DC
capacity to up-modulate CD83 and secrete TNF in response to
LPS. Conversely, IL-12 production was not rescued even after
medium replacement. Thus, bLF interaction with monocytes may
affect very early stages of their differentiation into DCs that, at
least under certain circumstances, translate into permanent
changes of activation related parameters. These changes, although
not apparently involving IL-6, may at least in part rely on soluble
factors released upon bLF addition.
bLF generated MD-DCs exhibit an impaired capacity to
induce T cell activation
Cells generated in the presence of bLF were further character-
ized for their functional properties. The capacity to induce T cell
activation was examined in allogenic mixed lymphocyte reactions
(MLRs). After stimulation with TLR agonists, bLF-MD-DCs
turned out to be weak activators of T cell proliferation, as
demonstrated by the drastically reduced number of lymphocytes
expressing Ki67, an intracellular antigen associated with DNA
replication, with respect to control activated cells (Figure 8A). In
keeping with these results, bLF-MD-DCs failed to prime naı ¨ve
allogenic CD4
+ T lymphocytes towards the expected Th1
polarization both in terms of percentage of IFN-c expressing cells
and the MFI for the IFN-c positive cells (Figure 8B). Accordingly,
IFN-c production was not detected in the supernatant of bLF-
MD-DC-T lymphocyte co-cultures with respect to control
activated MD-DCs (data not shown). However, bLF-mediated
impairment in IFN-c production did not favour the expression of
IL-4, since the low frequency of IL-4 producing cells was
comparable in all experimental conditions (Figure 8B). Likewise,
no IL-10 secretion was detected in the co-culture medium of both
bLF exposed and control cultures (,32.5 pg/ml for each
experimental point; n=5, mean 6 SE). A deeper characterization
of T lymphocytes in MLRs unravelled a very low intracellular
expression of the T lymphocyte activation marker CD154,
comparable to that observed in iMD-DCs, in CD4
+ T cells co-
cultured with bLF-MD-DCs activated with TLR agonists with
respect to T lymphocytes primed by activated control MD-DCs
(Figure 8C). In keeping with the functional unresponsiveness of
bLF-MD-DC primed T lymphocytes, a marked reduction in IL-2
content was found in LPS activated bLF-MD-DC/T lymphocyte
co-culture supernatants with respect to those collected from
control MD-DC/T lymphocyte co-cultures (Figure 8D). To
exclude the possibility that the hyporesponsiveness induced by
bLF-MD-DCs could be due to the preferential expansion of
naturally occurring T regulatory cells, we characterized the
phenotype of expanded CD4
+ T cells. However, no major
differences were observed in the percentage of FoxP3
+/CD25
high
T cells in MLRs with MD-DCs generated or not in the presence of
bLF (Figure 8E).
bLF promotes SOCS-3 and IDO expression
Enhanced suppressor of cytokine signaling-3 (SOCS-3) expres-
sion in murine DCs has been reported to block the IL-12/IL-23
signaling in these cells and to drive them toward a tolerogenic
phenotype promoting Th2 responses in vitro and in vivo [27].
Likewise, indoleamine 2,3-dioxygenase (IDO) activity in DCs has
been suggested to impair T cell responses by altering the
microenvironment at the DC/T cell interface [28]. Therefore,
to further elucidate the mechanisms by which bLF stimulation of
monocytes generates DCs with an impaired capacity to undergo
activation and immunosuppressive potential, SOCS-3 and IDO
expression was examined in bLF-MD-DCs. As shown in Figure 9,
SOCS-3 expression was detected in control immature MD-DCs.
However, when MD-DCs were generated in the presence of bLF a
clear-cut up-modulation of SOCS-3 was observed. Conversely,
despite the fact that IDO expression was not detected in control
iMD-DCs, a marked induction of the expression of this enzyme
was observed in bLF-MD-DCs. Interestingly, although IL-6 has
been reported to up-modulate SOCS-3 in APCs [29] blocking its
biological activity does not inhibit, but rather up-modulate,
SOCS-3 expression. Likewise, IDO expression was up-modulated
in bLF-MD-DC cultures in which IL-6 activity has been
suppressed (Figure 9).
p values were calculated comparing the percentage of bLF positive cells at day 1, 2, 3, 4, and 5 versus day 0. * p,0.05, ** p,0.01, *** p,0.001. (D) At
each time points, IL-6 produced after a 18 h treatment with bLF was measured by ELISA. Mean 6 SE of 3 independent experiments is shown.
doi:10.1371/journal.pone.0022504.g005
Figure 6. Role of CD14, TLR2 and TLR4 in bLF induced IL-6
production. Monocytes were pre-treated for 30 minutes with anti-
CD14, anti-TLR2, anti-TLR4 or isotype Ab prior to bLF addition and then
cultured for 6 days. Figure shows the mean 6 SE of 4 independent
experiments. Significance, calculated from raw data of 7 independent
donors, has been evaluated comparing cells treated with bLF in the
presence of isotype Ab to cells treated in the presence of Ab against
TLR2, TLR4 or CD14 (isotype versus TLR2, n=8, ***p,0.001; isotype
versus CD14, n=7, **p,0.01; isotype versus TLR4, n=8, *p,0.05).
doi:10.1371/journal.pone.0022504.g006
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22504Figure 7. bLF-mediated effects in monocytes and iMD-DCs. (A) Monocytes were plated in complete medium containing GM-CSF and IL-4.
Soon after seeding, cells were pre-treated for 30 minutes with neutralizing anti-IL-6 or isotype mAbs (5 mg/ml) or left untreated, then exposed to bLF.
Treatments were repeated at day 3 and 6 of culture, and proteins were extracted 6 h after the last treatment. Immunoblotting analysis for the
indicated proteins in control and bLF-exposed iMD-DCs. Samples containing 20 mg of lysate in Laemmli buffer were separated by 10% SDS-PAGE.
One representative experiment out of 6 is shown. (B) Monocytes were cultured as indicated in panel A. Twenty-four h after last treatment, cells were
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In this study, we report that human monocytes differentiated
into DCs in the continuous presence of bLF exhibit most of the
features of immature DCs but, upon TLR stimulation, do not
acquire the phenotypic and functional properties of mature DCs as
assessed by impaired up-modulation of activation related mole-
cules and cytokines, and retention of high endocytic activity.
Accordingly, bLF-MD-DCs exhibit a reduced capacity to promote
the expansion of IFN-c producing Th1 cells. However, bLF
neither favours the expression of IL-4 nor modulates IL-10
production, suggesting that this molecule might control the extent
of Th1 polarization rather than per se promoting a shift towards
Th2 responses. Phenotypic and functional characterization of T
lymphocytes primed by TLR agonist activated bLF-MD-DCs
revealed a less activated phenotype, as assessed by a reduced
expression of CD154, and a markedly diminished ability to
produce IFN-c and IL-2, suggesting a state of reduced function,
namely anergy [30]. In keeping with this assumption, functional
unresponsiveness of T lymphocytes has been characterized as a
profound inability of CD4
+ T cells to produce IL-2 in vitro [31].
Moreover, Andersen and co-workers showed that DCs generated
in tolerogenic environments are capable to induce anergy in
memory T cells and to skew cytokine polarization toward low IFN-
c/high IL-10 profile of naı ¨ve T cells [32]. Interestingly, anergy
induction in memory T cells does not rely on the expansion of
CD25
high T regulatory cells, and is partially reversed by IL-2.
Conversely, the addition of exogenous IL-12 during DC/T cell
priming preventes anergy induction in memory T cells and
cytokine polarization in naı ¨ve T cells. Accordingly, we were
unable to detect a preferential expansion of CD4
+/CD25
high T
regulatory cells in T cell cultures primed by bLF-MD-DCs.
Previous studies reported that TLR stimulation during the
period of DC generation interferes with and deviates DC
differentiation [33,34,35,36]. In this regard, it could be argued
that minimal amounts of LPS bound to bLF might have a role in
the generation of tolerogenic-like DCs we described. However,
experimental evidence argues against this conclusion. Specifically,
we observed that blocking LPS activity by polymixin B does not
completely abrogate bLF capacity to induce IL-6 (data not shown).
In addition, we clearly demonstrated that the maturation arrest of
bLF-MD-DCs does not merely depend on the capacity of this
molecule to sequester LPS [21], as similar results have been
achieved when poly(I-C) or R848 were used. Finally, bLF-MD-
DCs do not show the differentiation block described for the MD-
DCs generated in the presence of low amounts of LPS [33,35].
However, our results indicate that bLF has the capacity to
modulate the CD1a
+/CD1a
2 ratio since a modest but significant
reduction in the number of CD1a
+ DCs has been detected in the
presence of bLF. Monocytes can give rise to two populations of
myeloid DCs differing in CD1a expression [12,13]. Interestingly,
activated CD1a
2 MD-DCs produce low levels of IL-12 but up-
modulate IL-10 secretion, exhibit a scarce capability to induce
IFN-c production and naı ¨ve CD4
+ Th1 polarization [12,13], and
can direct differentiation of Th0/Th2 cells [37]. Although a
detailed characterization of the functional properties of bLF-
induced CD1a
2 cells has not been performed, the capacity of bLF
to modulate the CD1a
+/CD1a
2 ratio suggests a role for this
compound in the in vivo-relevant pathway of monocyte differen-
tiation into DCs.
DCs have a pivotal role in both the priming of adaptive immune
responses and the induction of self-tolerance. This latter function is
mediated by specialized subsets of DCs, named tolerogenic DC, as
well as by DC activated or differentiated in the presence of specific
biological or chemical agents [11]. They all share the ability to
negatively regulate T cell responses, yet their phenotypes, cytokine
profiles and thus their mode of action are divergent [11]. In this
regard, it has been reported that expression of PD-L1, mainly
described as a negative regulatory molecule, is linked with the
ability of DCs to induce tolerance [38,39]. Likewise, the inhibitory
receptor ILT3 has been shown to negatively regulate APC
activation [40]. Interestingly, both molecules are up-modulated in
bLF-MD-DCs suggesting that they may play a role in the negative
regulation of T cell function.
Among the factors described to drive the generation of
tolerogenic DCs is IL-6 [41]. This cytokine is now considered as
an important mediator of the immune response especially by
directly acting on CD4
+ T cells and determining their effector
functions [41,42]. Furthermore, this cytokine promotes monocyte
differentiation into tolerogenic DCs unable to produce TNF and
IP-10, to induce allogenic T cell proliferation, and to express
CCR7 [22]. Likewise, circulating DCs isolated from multiple
myeloma patients exhibit an impaired capacity for T cell
stimulation that is partly caused by IL-6-mediated inhibition of
DC development [43]. However, it remains an open question how
IL-6 orchestrates all these different functions but the presence of
other factors will probably be a likely explanation. Studies
performed in mouse models have enlighten a major role for IL-
6/STAT3 signalling pathway in maintaining tolerance in vivo
[23,44]. In our study, we show that bLF exposed monocytes
transiently produce high amounts of IL-6 soon after treatment,
and this cytokine is responsible for the hyper-activation of STAT3
observed in these cells. However, blocking the biological activity of
this cytokine neither rescues LPS-induced up-modulation of
CD83, TNF and IL-12 nor inhibits, but rather up-modulates,
the expression of tolerance related molecules, hyper-expressed in
bLF-MD-DCs, such as SOCS-3 [27] and IDO [28]. Our results
that IL-6 blocking is not sufficient to counteract the tolerogenic-
like phenotype of bLF-MD-DCs argue against a role of this
cytokine in the bLF-mediated effects. However, the observation
that bLF induces IL-6 secretion and downstream STAT3
activation in monocytes but not in MD-DCs that conversely
respond to bLF by up-modulating their immunostimulatory
potential [17,18], suggests that other not yet identified aspects of
DC functional activation could rely on IL-6.
In this study, we report for the first time that bLF is rapidly
internalized by freshly isolated monocytes, but not iMD-DCs, and
reaches the nucleus. Interestingly, an intimate relationship
between differentiation progression and capacity of bLF to reach
the nucleus was also found. The nuclear localization of LF suggests
that this molecule may be involved in the transcriptional
regulation of genes ultimately controlling monocyte differentiation.
In this regard, co-transfection experiments in which a LF
stained with anti-CD83 or isotype mAbs and supernatants assessed for cytokine content. One representative experiment out of 4 is shown for CD83
expression. IL-12 and TNF expression is shown as mean 6 SE of 3 independent experiments. (C–D) Soon after seeding or at day 5 of culture, cells were
treated with bLF for 18 h, then medium was or not replaced with fresh medium (replaced medium and original medium, respectively). At day 5 cells
were stimulated with LPS for 24 h. The expression of CD83, IL-12 and TNF in MD-DCs, cultured without or in the continuous presence of bLF (original
medium) or exposed to bLF for 18 h (replaced medium) was assessed by FACS analysis and ELISA, respectively. Open and dashed areas represent
CD83 expression in cells exposed or not to bLF, respectively. One representative experiment out of 3 performed is shown.
doi:10.1371/journal.pone.0022504.g007
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e22504Figure 8. bLF inhibition of DC-mediated T cell responses. Monocytes were cultured as described in the legend to Figure 1 then stimulated
with LPS and poly(I-C) for 24 h. (A) At day 6, MD-DCs were collected and co-cultured with allogenic PBL at ratio DC/PBL of 1:100. At day 9, PBL were
intracellularly stained with FITC-conjugated mAb against Ki67. FACS analysis was performed on lymphocyte population according to FSC/SSC
parameters. Percentage of proliferating T lymphocytes is shown. 20.000 events were acquired per sample. (B) and (C) At day 6, DCs were co-cultured
with allogenic CD4
+ naive T cells at ratio DC/T of 1:10 for 5 days, then stimulated with PMA (50 ng/ml) and ionomycin (1 mg/ml) then intracellularly
stained with mAb to polarizing cytokines and the activation marker CD154. (B) Expression of IFN-c and IL-4 in CD4
+ T cells. FACS analysis was
performed by gating in the region of activated lymphocytes. Numbers indicate the percentage of lymphocytes included in each quadrant. (C)
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reporter gene linked to the GM-CSF promoter, revealed that LF
reduces the activity of the GM-CSF promoter [45]. Consistent
with these results, we found that bLF nuclear localization
correlates with bLF capacity to stimulate IL-6 expression. The
different capacity of monocytes to interact with bLF with respect
to iMD-DCs may provide, at least in part, an explanation for the
opposite effects, anti-inflammatory versus immunostimulatory
[17,18], observed in these cell types.
The mechanism of LF entry is still unknown, but is thought to
occur via a LF receptor. LF is a cationic protein capable to bind,
with different grade of specificity, a variety of cellular determi-
nants, including bacterial components, strongly anionic molecules,
CD14, and pathogen recognition receptors including C-type lectin
receptors and TLR4 [1,19,21,46]. Although the relevance of these
receptors in triggering bLF effects in human primary monocytes
and MD-DCs is unknown, it is of interest that major differences in
the expression of at least some of these receptors (e.g. CD14 and
DC-SIGN) have been reported in monocytes versus iMD-DCs. In
particular, CD14 takes part in receptor complexes that play a
crucial role in governing inflammation such as TLR4 [47] and
TLR2 [48] pathways. In this regard, our study demonstrates that
although not involved in bLF uptake by monocytes, CD14 and its
co-receptors TLR2 and TLR4 play a role in bLF-induced
signalling leading to IL-6 expression. Since CD14 is barely or
not expressed at all in MD-DCs, these results suggest that this
receptor may represent an important determinant for the
differential effects induced by bLF in the two cell types.
Taken together these results shed some light on the mechanisms
underlying bLF anti-inflammatory activity, highlighting the
importance of monocytes as a preferential target for this molecule,
and providing further support to its potential therapeutic
application to inflammatory diseases.
Materials and Methods
Cell separation and culture
Peripheral blood mononuclear cells (PBMCs) were isolated from
the peripheral blood of healthy donors by Ficoll-Paque density
centrifugation [49]. Monocytes were further purified by depleting
the non monocytic population by immunomagnetic bead selection
as previously described [50]. Immature MD-DCs were generated
by culturing monocytes in RPMI supplemented with 10% FBS
containing GM-CSF and IL-4 (50 ng/ml and 500 U/ml,
respectively, kindly provided by Schering-Plough, Dardilly,
France) in the presence or in the absence of bLF (100 mg/ml) as
previously described [51]. Freshly isolated monocytes were treated
with bLF in the presence of differentiating factors soon after
seeding, at day 2 and day 5 of culture, unless differently specified.
Reagents
All culture reagents were purchased as endotoxin-free lots
(Biowhittaker). LPS from Escherichia Coli (serotype EH100, Ra
TLRgrade, Alexis Biochemicals), and poly(I-C) by Sigma.
Resiquimod (R848) was a gift of Philippe Neuner (Istituto
Ricerche di Biologia Molecolare, Pomezia, Italy). Highly purified
bLF in lyophilized form was kindly provided by Morinaga Milk
Industries Co., Ltd., (Tokyo, Japan). bLF was checked for purity
[52], iron saturation and endotoxin content as previously
described [52]. Monoclonal Abs (mAbs) against TLR4 [53]
(5 mg/ml, clone 15C1) and TLR2 [54] (5 mg/ml, clone T 2.5)
were kindly provided by Greg Elson. Monoclonal Abs against
CD14 (5 mg/ml, clone 134620) and IgG1k isotype control Abs
(5 mg/ml, clone 11711) were purchased from R&D. MD-DC
phenotype was characterised by using the following mAbs: FITC-
CD1a and PE-CD1a (clone HI149), FITC-CD14 and PE-CD14
(clone MWP9), FITC-CD40 (clone 5C3), FITC-CD80 (clone
L307.4), FITC-CD86 (clone 2331(FUN-1)), FITC-CD83 (clone
HB15e), FITC-HLA-DR (clone G46-6), FITC-HLA-ABC (clone
G46-2.6), FITC-ILT3 (clone 293623, R&D), FITC-ILT4 (clone
287219, R&D), PE-CD274 (PD-L1, clone MIH1), PE-CD206 MR
(clone 19.2), mouse purified anti-CD209 (DC-SIGN, DCN46)
followed by FITC-goat-anti-mouse IgG (H+L) F(ab’)2 (PIERCE).
Non specific binding was checked by the respective isotype Abs
FITC-IgG2a (G155-178), FITC-IgG1 and PE-IgG1 (clone
MOPC-21), FITC-IgG2a (clone 20102, R&D), purified mouse
IgG2bk (clone 27–35). Unless differently indicated, mAbs were
purchased from BD Biosciences. Briefly, 2–5610
5 cells were
processed and labelled as previously described [55]. Samples were
acquired with a FACS Calibur flow cytometer by using Cell Quest
(Becton Dickinson) and data analyzed by FlowJo (Tree Star, Inc.).
Antigen-uptake assay
MD-DCs were stimulated with LPS or poly(I-C) at day 6 of
culture. 24 h later, cells were washed and incubated with FITC-
labeled DXT (Molecular Probe, 500 mg/sample) for 40 min at
37uC, or 0uC to test unspecific binding. Cells were then fixed in
PBS/4%PFA and analyzed by flow cytometry.
DC-T cell cultures and Th profile
Allogenic CD4
+ naı ¨ve T cells were isolated from PBMC of
healthy donors by using naı ¨ve CD4
+ T cell isolation Kit II
(Miltenyi Biotech) and co-cultured in RPMI 5% human AB pool
serum with MD-DCs or bLF-MD-DCs primed with LPS (10 ng/
Expression of CD154. A minimum of 40.000 events were acquired per sample. (D) At day 6, cells were co-cultured with allogenic CD4
+ naive T cells at
ratio DC/T of 1:10 for 7–10 days. Supernatants were analyzed by ELISA for IL-2 content. IL-2 production is shown as mean 6 SE (LPS, n=7; poly(I-C),
n=5). Significance was evaluated comparing MD-DCs to bLF-MD-DCs co-cultures. * p,0.05 and *** p,0.001, for poly(I-C) and LPS, respectively. (E)
FACS analysis of intracellular FoxP3 protein at the single cell level. CD4
+ naive T cells were primed with control or LPS-activated MD-DCs or bLF-MD-
DCs and further re-stimulated with DCs of the same donor before staining with Abs and FACS analysis. A representative FACS profile is shown as dot
plots of FITC-CD25 versus APC-FoxP3. The quadrant gates were set according to the negative isotype control Abs in the respective experimental
conditions. Numbers indicating the percentage of cells included in each quadrant are shown.
doi:10.1371/journal.pone.0022504.g008
Figure 9. Expression of SOCS3 and IDO in bLF-MD-DCs. Cells
were treated as described in the legend to Figure 6A. Immunoblotting
analysis for the indicated proteins in control and bLF-exposed iMD-DCs
is shown. Samples were resolved in 10% SDS-PAGE gels. One
representative experiment out of 5 is shown.
doi:10.1371/journal.pone.0022504.g009
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6 T
cells/well in 24-well plates. At day 5, supernatants were collected
for cytokine determination while cells were extensively washed,
re-suspended in fresh medium at 1610
6 cell/ml and stimulated
with ionomycin (2 mg/ml) and PMA (50 ng/ml) (both from
Sigma-Aldrich) for 5 h. Golgi Stop (BD Bioscience) was added
during the last 3 h of culture following the manufacturer’s
instructions. After stimulation, CD4
+ T cells were fixed,
permeated using Cytofix/Cytoperm Plus
TM (BD Bioscience)
and processed for intracellular staining with Fastimmune FITC-
IFN-c/PE-IL-4 cocktail (clones 25723.11 and 3010.211 respec-
tively, BD Bioscience), and PE-CD154 [56] (clone TRAP1, BD
Bioscience). Cells were also stained with the respective isotype
Abs mouse FITC-IgG2a/PE-IgG1 (clones 639/640, BD Biosci-
ences) and mouse PE-IgG1 (MOPC-21, BD Biosciences).
Alternatively, allogenic CD4
+ naı ¨ve T cells were primed with
LPS-activated MD-DCs or bLF-MD-DCs at T/DC ratio of 1:10
for 7–10 days and successively re-stimulated with allogenic
cryopreserved DCs of the same donor. Seven-to ten days after last
stimulation, cells were processed for surface staining with FITC-
CD25 (clone M-A251, BD Biosciences), then fixed and
permeated for intracellular APC-FoxP3 (clone PCH101,
eBioscience) staining and FACS analysis.
T cell proliferation assay
MD-DCs were co-cultured at different DC/T cell ratio,
starting from 1:10, with peripheral blood lymphocytes (PBL),
obtained from PBMCs after depletion of CD14
+ cells. After 5–10
days, cells were fixed and permeated as above described, then
stained with Ki67 and the relative isotype Ab, following the
manufacturer’s instructions (FITC Mouse Anti-Human Ki67 Set,
BD Biosciences).
Determination of cytokine and chemokine levels
Culture supernatants were processed by ELISA for the
following cytokines: TNF, IL-12, IL-10 (sensitivity 32.5 pg/ml,
homemade assay, Pierce Endogen), IL-6 (sensitivity 7.8 pg/ml,
ELISA MAX
TM Set, BioLegend), CCL2 (sensitivity 15.6 pg/ml,
homemade assay, R&D System), IL-23 (sensitivity 31 pg/ml,
eBioscience) and IL-2 (sensitivity 7.8 pg/ml, ELISA MAX
TM Set,
BioLegend).
Cytoplasmic proteins expression analysis
Immunoblotting analysis of STAT3, SOCS-3 and IDO was
carried out in cells differentiated for 6 days in the presence or in
the absence of bLF. Endogenously produced IL-6 was neutralized
by anti-human-IL-6 (5 mg/ml, clone 6708.11, SIGMA) or IgG1k
isotype control (5 mg/ml, clone 11711, R&D) mAbs. Cells were
pre-treated at day 0, 3 and 6 with anti-IL-6 for 30 min, before bLF
addition to the cultures. Six h after the last bLF treatment whole
cell proteins were extracted as previously described [57]. The
protein concentration was determined using the Bio-Rad protein
assay (Hercules, CA) according to the manufacturer’s instructions.
Twenty micrograms of lysate was separated by SDS-PAGE on a
10% gel and electroblotted to nitrocellulose filter (Protran BA 85,
Schleicher & Schuell, Keene, NH). The following Abs were used:
rabbit polyclonal Ab anti-phospho-STAT3 (Y705; Cell Signaling
Technology, diluted 1:1000), mouse mAb anti-STAT3 (BD
Transduction Laboratories, diluted 1:2500), anti-Actin Ab-5 (BD
Biosciences, diluted 1:5000), anti-SOCS-3 (Santa Cruz Biotech-
nology, diluted 1:500) and anti-IDO (Upstate, diluted 1:500).
Signals were revealed after incubation with anti-mouse or anti-
rabbit Ig HRP secondary Ab followed by ECL detection reagent
(Amersham).
Confocal laser-scanner microscopy analysis (CLSM)
Cells were fixed with 1% PFA for 15 min at room temperature
(RT), and permeabilized with Dulbecco’s PBS (DPBS), containing
Ca
++ and Mg
++, 1% BSA and 0,1% Triton X-100 (Sigma-Aldrich
Co.) for 30 min at RT. Cells were stained with a 1:50 dilution in
DPBS/0.1% BSA of FITC-conjugated polyclonal rabbit anti-
human LF Ab (DakoCytomation) for 1 h at RT. As a negative
control, the primary Ab was omitted. Cells were then extensively
washed with DPBS and stained with the nuclear fluorescent probe
TO-PRO-3 (1 mM, Molecular Probes) for 15 min at RT. After
several rinses, cover slips were mounted in buffered glycerol (pH 9)
and sealed with nail polish. Immunofluorescence imaging was
performed using a Leica confocal microscope (Laser Scanning
TCS SP2) equipped with Ar/ArKr and He/Ne lasers at 640
magnification under an oil-immersion lens. A series of 12 optical
sections with a step size of 1 mm through cells were acquired. Laser
line was at 488 nm and 633 nm for FITC and TO-PRO-3
excitation, respectively. The percentage of positive cells was
calculated by analyzing at least 350 cells for each experimental
sample.
Statistical analysis
Statistical comparison between different experimental condi-
tions was determined by the Student’s t test (paired, two-tailed) by
using SPSS software. Differences were considered significant when
p values were ,0.05 (*), ,0.01 (**), ,0.001(***).
Supporting Information
Figure S1 bLF induced impairment of R848-induced
MD-DC maturation. Monocytes were stimulated to differen-
tiate into iMD-DCs in the presence or in the absence of bLF as
described in the legend to Figure 1. At day 5 of culture, cells were
stimulated with R848 (2 mg/ml). (A) Twenty-four hours later, cells
were collected and stained with a mAb to CD83. Open area
represents staining with isotype Ab and shaded area CD83
expression in activated control and bLF-MD-DCs. Numbers
indicate MFI. One representative experiment out of 3 is shown.
(B–C) IL-12 and TNF contents in supernatants of MD-DCs
stimulated with R848 for 24 h. Mean 6 SE of 3 independent
experiments is shown. ** p,0.01, MD-DCs versus bLF-MD-DCs.
(TIF)
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